Rebecca Limer is an Associate in the Intellectual Property (IP) team. She works across a range IP rights and advises clients on both contentious and non-contentious matters.
Rebecca recently acted for GSK in its High Court patent dispute with Vectura (Glaxo Group Limited & Ors v Vectura  EWHC 3414 (Pat) (13 December 2018)). A notable case in which GSK succeeded on both its Gillette defence, despite the judge declining to find Vectura's patents in suit obvious (though they were found invalid for insufficiency, by way of ambiguity), and its claim for an Arrow declaration. The declaration being only the second to be granted in the UK.
In addition to her contentious work Rebecca has, since qualification, assisted on a number of IP deals for clients in the pharmaceutical and biotech industry. She also regularly advises clients from a range of business sectors on the IP aspects of their corporate transactions.
Prior to qualification Rebecca assisted the Gowling WLG team representing Fujifilm in Fujifilm Kyowa Kirin Biologics Co Ltd v AbbVie  EWHC 395 (Pat). This case resulted in Fujifilm being awarded a declaration confirming the obviousness of its own products, an Arrow Declaration, the first of its kind in the UK, which cleared the way for the launch of Fujifilm's biosimilar to AbbVie's blockbuster drug, Humira.
Rebecca has previous experience and a particular interest in the life sciences sector. Prior to joining the firm Rebecca worked in contract management roles for a multinational healthcare business, where she focused on medical imaging R&D projects, and a leading cancer research institute, where she was responsible for negotiating commercially sponsored clinical trials contracts and other industry collaboration agreements."